Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer

Abstract

Acquired resistance to chemotherapy is a major limitation in clinical treatment for breast cancer. Accumulating evidence from in vitro, in vivo and clinical studies suggest that acquired chemoresistance is progressive, multifactorial and involve genetic and epigenetic aberrations. Among various mechanisms that contribute to chemoresistance, cellular reprogramming has extensively been implicated in breast cancer resistance lately. Cellular reprogramming events such as acquisition of epithelial to mesenchymal transition (EMT) and cancer stemness (CSCs) not only provide cancer cells with reversible phenotypic plasticity and survival advantage against cytotoxicity but also leads to aggressiveness, metastasis, clinical resistance, tumor recurrence and poor survival. The transient and reversible nature of cellular reprogramming processes and their controlled interaction with epigenetic regulatory complexes strongly support the involvement of dynamic epigenetic regulatory network in governing the cellular reprogramming and associated acquired chemoresistance. Further, epigenetic modulations are also gaining interest as promising interventions addressing the cancer cell reprogramming machinery to overcome acquired chemoresistance. This review discusses the previous reports and our recent findings that lead to current understanding of epigenetic dysregulation dictating the cellular reprogramming processes such as acquisition of EMT and CSCs phenotype and how they co-ordinate to establish acquired drug resistance in breast cancer.

Keywords

Chemoresistance / cellular reprogramming / DNA methylation / histone modifications / breast cancer / epithelial to mesenchymal transition / cancer stem cell

References

[1] Tong CWS,Cho WCS.Recent advances in the treatment of breast cancer..Front Oncol2018;8:227 PMCID:PMC6010518

[2] Wind NS.Multidrug resistance in breast cancer: from in vitro models to clinical studies..Int J Breast Cancer2011;2011:967419 PMCID:PMC3276077

[3] Hong D,Zaidi SK,Nickerson JA.Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity..J Cell Physiol2018;233:9136-44 PMCID:PMC6185773

[4] Mansoori B,Davudian S,Baradaran B.The different mechanisms of cancer drug resistance: a brief review..Adv Pharm Bull2017;7:339-48 PMCID:PMC5651054

[5] Housman G,Heerboth S,Longacre M.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[6] Wainwright EN.Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity..trends cancer2017;3:372-86 PMCID:PMC5506260

[7] Skrypek N,De Smedt E,Berx G.Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity..Trends Genet2017;33:943-59

[8] Nickel A.Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells..Transl Res2015;165:126-42

[9] Lee JY.Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression..Cell Mol Life Sci2016;73:4643-60

[10] Serrano-Gomez SJ,Alahari SK.Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications..Mol Cancer2016;15:18 PMCID:PMC4765192

[11] Ravasio R,Minucci S.Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype..Curr Opin Genet Dev2016;36:92-9

[12] He DX,Gao F,Gong D.Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer..Sci Rep2016;6:24706 PMCID:PMC4837395

[13] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications..Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[14] Liu X.The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links..Curr Pharm Des2015;21:1279-91

[15] Sin WC.Breast cancer stem cells-from origins to targeted therapy..Stem Cell Investig2017;4:96 PMCID:PMC5723743

[16] Liu S,Wang D,Deng L.Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts..Stem Cell Reports2014;2:78-91 PMCID:PMC3916760

[17] Chaffer CL,Lee T,Kleer CG.Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity..Cell2013;154:61-74 PMCID:PMC4015106

[18] Nishi M,Akutsu H,Quinn G.Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors..Oncogene2014;33:643-52 PMCID:PMC4697746

[19] Liao WT,Deng YJ,Ding YQ.Metastatic cancer stem cells: from the concept to therapeutics..Am J Stem Cells2014;3:46-62 PMCID:PMC4163604

[20] Calcagno AM,Gillet JP,Fostel JM.Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics..J Natl Cancer Inst2010;102:1637-52 PMCID:PMC2970576

[21] Phi LTH,Yang YG,Jun N.Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment..Stem Cells Int2018;2018:5416923 PMCID:PMC5850899

[22] Sharma SV,Li B,Takahashi F.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations..Cell2010;141:69-80 PMCID:PMC2851638

[23] Wilting RH.Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance..Drug Resist Updat2012;15:21-38

[24] Blick T,Widodo E,Pinto C.Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer..J Mammary Gland Biol Neoplasia2010;15:235-52

[25] Yenigun VB,Kose GT.Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen and doxorubicininduced autophagy..Int J Mol Med2013;31:1477-83

[26] Mani SA,Liao MJ,Ayyanan A.The epithelial-mesenchymal transition generates cells with properties of stem cells..Cell2008;133:704-15 PMCID:PMC2728032

[27] Lamouille S.Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway..J Cell Biol2007;178:437-51 PMCID:PMC2064840

[28] Sakaki-Yumoto M,Derynck R.TGF-beta family signaling in stem cells..Biochim Biophys Acta2013;1830:2280-96 PMCID:PMC4240309

[29] Vervoort SJ,van Boxtel R.SOX4 mediates TGF-beta-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition..PLoS One2013;8:e53238 PMCID:PMC3536747

[30] Lee JJ,Yap YS.PI3K/Akt/mTOR inhibitors in breast cancer..Cancer Biol Med2015;12:342-54 PMCID:PMC4706528

[31] Dhasarathy A,Wade PA.The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha..Mol Endocrinol2007;21:2907-18 PMCID:PMC2668600

[32] Jang GB,Cho SD,Jung JY.Blockade of Wnt/beta-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype..Sci Rep2015;5:12465 PMCID:PMC5378883

[33] Takahashi-Yanaga F.Targeting Wnt signaling: can we safely eradicate cancer stem cells?.Clin Cancer Res2010;16:3153-62

[34] Zhan T,Boutros M.Wnt signaling in cancer..Oncogene2017;36:1461-73 PMCID:PMC5357762

[35] Li J.Activation of beta-catenin and Akt pathways by twist are critical for the maintenance of EMT associated cancer stem cell-like characters..BMC Cancer2011;11:49 PMCID:PMC3040162

[36] Deshmukh A,Arfuso F,Dharmarajan A.Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines..Sci Rep2017;7:2256 PMCID:PMC5442130

[37] Ponnusamy L,Singh KP.Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells..Eur J Pharm Sci2017;104:424-33

[38] Katoh Y.Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation..Curr Mol Med2009;9:873-86

[39] Wils LJ.Epigenetic regulation of the hedgehog and Wnt pathways in cancer..Crit Rev Oncol Hematol2018;121:23-44

[40] Wang Z,Kong D.The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness..Curr Drug Targets2010;11:745-51 PMCID:PMC3084452

[41] Chen W,Liu S.Cytokines, breast cancer stem cells (BCSCs) and chemoresistance..Clin Transl Med2018;7:27 PMCID:PMC6119679

[42] Suman S,Damodaran C.Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells..Br J Cancer2013;109:2587-96 PMCID:PMC3833225

[43] Dong C,Yao J,Yu Y.G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer..J Clin Invest2012;122:1469-86 PMCID:PMC3314447

[44] Kondo Y.Epigenetic cross-talk between DNA methylation and histone modifications in human cancers..Yonsei Med J2009;50:455-63 PMCID:PMC2730606

[45] Marmorstein R.Histone modifying enzymes: structures, mechanisms, and specificities..Biochim Biophys Acta2009;1789:58-68 PMCID:PMC4059211

[46] Nair SS.Chromatin remodeling in cancer: a gateway to regulate gene transcription..Mol Oncol2012;6:611-9 PMCID:PMC3538127

[47] Dey P.Chromatin remodeling, cancer and chemotherapy..Curr Med Chem2006;13:2909-19

[48] Chen D,Li Y,Yuan Q.Targeting BMI1(+) cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma..Cell Stem Cell2017;20:621-34 e6 PMCID:PMC5419860

[49] Cao R,Wang H,Erdjument-Bromage H.Role of histone H3 lysine 27 methylation in polycomb-group silencing..Science (New York, NY)2002;298:1039-43

[50] Santos-Rosa H.Chromatin modifier enzymes, the histone code and cancer..European journal of cancer (Oxford, England : 1990)2005;41:2381-402

[51] Vaissiere T,Herceg Z.Epigenetic interplay between histone modifications and DNA methylation in gene silencing..Mutat Res2008;659:40-8

[52] Crea F,Farrar WL.Cancer stem cell epigenetics and chemoresistance..Epigenomics2009;1:163-79

[53] Chekhun VF,Kovalchuk O,Pogribny IP.Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets..Mol Cancer Ther2007;6:1089-98

[54] Teodoridis JM,Plumb JA.CpG-island methylation and epigenetic control of resistance to chemotherapy..Biochem Soc Trans2004;32:916-7

[55] Seligson DB,McBrian MA,Yu H.Global levels of histone modifications predict prognosis in different cancers..Am J Pathol2009;174:1619-28 PMCID:PMC2671251

[56] Patra SK,Patra A.Molecular marks for epigenetic identification of developmental and cancer stem cells..Clin Epigenetics2011;2:27-53 PMCID:PMC3365374

[57] Poli V,Zippo A.Tumorigenic cell reprogramming and cancer plasticity: interplay between signaling, microenvironment, and epigenetics..Stem Cells Int2018;2018:4598195 PMCID:PMC5954911

[58] Menendez JA,Cuyas E,Fernandez-Arroyo S.Oncometabolic nuclear reprogramming of cancer stemness..Stem Cell Reports2016;6:273-83 PMCID:PMC4788754

[59] Aubele M,Napieralski R,Ettl J.The predictive value of PITX2 DNA methylation for high-risk breast cancer therapy: current guidelines, medical needs, and challenges..Dis Markers2017;2017:4934608 PMCID:PMC5613359

[60] Nass SJ,Gabrielson E,Parl FF.Aberrant methylation of the estrogen receptor and E-cadherin 5’ CpG islands increases with malignant progression in human breast cancer..Cancer Res2000;60:4346-8

[61] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters..Nat Rev Cancer2002;2:48-58

[62] McDonald OG,Timp W,Feinberg AP.Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition..Nat Struct Mol Biol2011;18:867-74 PMCID:PMC3150339

[63] Ke XS,Cheng Y,Rotter V.Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells..BMC Genomics2010;11:669 PMCID:PMC3012672

[64] Lombaerts M,Philippo K,Zimmerman RM.E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines..Br J Cancer2006;94:661-71 PMCID:PMC2361216

[65] Xiao XS,Chen JW,Kung HF.High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis..Chin J Cancer Res2011;23:201-7 PMCID:PMC3587557

[66] Liao ZW,Cai MY,He LR.P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line..Oncol Lett2017;13:763-9 PMCID:PMC5351396

[67] Li QQ,Wang WJ,Chen Q.Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells..Clin Cancer Res2009;15:2657-65

[68] Zhang X,Zhang Q,Sun P.ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM..Cell Death Dis2018;9:57 PMCID:PMC5833408

[69] Fu J,He T,Hong J.The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis..Cell Res2011;21:275-89 PMCID:PMC3193433

[70] Peng L,Ling H,Robertson K.SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities..Mol Cell Biol2011;31:4720-34 PMCID:PMC3232929

[71] Pourakbar S,Accurso AD.Ezh2, a novel target in detection and therapy of breast cancer..Onco Targets Ther2017;10:2685-7 PMCID:PMC5449122

[72] Lee JY,Park JH,Shin DH.Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer..Oncogene2014;33:1325-35

[73] Yang F,Li Q,Lei L.SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities..EMBO J2012;31:110-23 PMCID:PMC3252577

[74] Cai J,Wang QS,Du X.FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer..Cancer Lett2015;367:129-37

[75] Fang X,Liu J,Wu Q.Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal..Oncogene2011;30:474707-20

[76] Siddique HR.Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences..Stem Cells2012;30:372-8

[77] Paranjape AN,Mandal T,Nagaraj P.Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog..BMC Cancer2014;14:785 PMCID:PMC4223733

[78] Ponnusamy L,Chang YW.Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells..Eur J Pharm Sci2018;123:56-69

[79] Toh TB,Chow EK.Epigenetics in cancer stem cells..Mol Cancer2017;16:29 PMCID:PMC5286794

[80] Suraweera A,Richard DJ.Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi..Front Oncol2018;8:92 PMCID:PMC5884928

[81] Copeland RA,Scott MP.Targeting epigenetic enzymes for drug discovery..Curr Opin Chem Biol2010;14:505-10

[82] Gomez-Casal R,Epperly MW,Wang H.The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells..Cancers (Basel)2015;7:876-907 PMCID:PMC4491689

[83] Walsh LA.IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-beta1 resulting in epithelial to mesenchymal transition..Cell Commun Signal2011;9:10 PMCID:PMC3104381